TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Nominal maximum heart dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum left anterior descending dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Target-lesion failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-h IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases of human immunodeficiency virus prevented
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cases of chlamydia prevented
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cases of gonorrhea prevented
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: combined rate of death or developmental delay
Endpoint domain: Mortality/survival
Primary endpoint: pathological complete or subtotal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight of African American children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Support for physical activity in African American children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress management level in white parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ktrans levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum BSE concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paratonia assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI (Clinical Global Impression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSC (Patient Specific Complaints)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PACSLAC-D (Pain Assessment Checklist for Seniors with Limited Ability to Communicate - Dutch version)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of correct assessments of incontinence associated dermatitis (IAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of correct classification of pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean depth of dye penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIV-specific CD8+GRZ+ T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HI antibody titers against A/H1N1 and A/H3N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cmax of roflumilast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0–24 h of roflumilast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean half-life (t1/2) of roflumilast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of alcohol-attributable diseases/injuries
Endpoint domain: Mortality/survival
Primary endpoint: Avoidance of deaths
Endpoint domain: Mortality/survival
Primary endpoint: helpfulness of virtual reality models for individualized planning of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative iron incorporation in erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: liver percentage enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pancreas-to-liver enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mild acute adverse event (vomiting)
Endpoint domain: Adverse events/effects
Primary endpoint: Parental situational anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of culture-positive tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Volume estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean final visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in visual acuity to worse than 20/200
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active treatment time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient preference for digital impressions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived job stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quality of physician-patient relationship
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Detection of cervical intraepithelial neoplasia 2/3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to testing and follow-up
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Recurrence of endometrial polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of uterine bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitral regurgitant volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular end-diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean MA circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutropenia grade 4
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalization for toxicity
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median hospitalization stay for toxicity
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Severity score of nocturnal dyspeptic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nocturnal duodenogastric bile reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean gastric pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PCO2 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neurologic development test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time without symptoms or toxicity (TWIST)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: relapse-free time
Endpoint domain: Mortality/survival
Primary endpoint: time alive
Endpoint domain: Mortality/survival
Primary endpoint: 28-week PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean heart rate (HR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: leakage pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of complete analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first request for additional analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: time to clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major infective episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of pulmonary exacerbations (PEx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adjusted incidence rate of pulmonary exacerbations (PEx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: induced sputum neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pseudomonas isolation agar colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean d(2-3)mfs increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: times of acceleration and deceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stability of the injured limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cecal intubation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of NEC
Endpoint domain: Adverse events/effects
Primary endpoint: low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: groin pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Center of ventilation during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ability Language strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Commitment Language strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent in educational activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Social networks
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Integration of Si-CaP into bone tunnel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filling rates in tibial tunnel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fragment retrieval ease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for fragment retrieval using a basket
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Body mass change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of shock within first hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sequential Organ Function Assessment score on day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ failure-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal motor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of the 8-week study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of correct responses
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Liver fat fraction (LFF) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum alanine aminotransferase (ALT) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA damage (tail moment and tail intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parental support for HSV-2 testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adolescent distress following positive HSV-2 results
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative emetic symptoms and headache
Endpoint domain: Adverse events/effects
Primary endpoint: Patient cooperation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Satisfactory comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma concentration of 5‐ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of 5‐ASA excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary recovery of total 5‐ASA plus Ac‐5‐ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCFA areas under the curve (AUC) from 4-6 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ghrelin at 6 h after IN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to task completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tool path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inattentional blindness
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Outcome Measurement (POM) at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vessel cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative remodelling frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of remitted participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: probability of depression diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to wean from mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ineligibility for the PORTEC‐3 trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean weight change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2RCP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: submaximal workload (WattRCP and SMW/HR ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in individual care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of switches into hypomania or mania
Endpoint domain: Adverse events/effects
Primary endpoint: Total encounter time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Assessment only component time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Documentation of pain and side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICAM-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitric oxide generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decreased survival
Endpoint domain: Mortality/survival
Primary endpoint: decreased disease-free interval
Endpoint domain: Mortality/survival
Primary endpoint: increased distant metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Participation rates among racial and ethnic minorities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: mean annual rate of corneal endothelial cell loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive breast cancer odds ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: stimulated fibrinogen binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RBC aggregation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: whole blood viscosity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Naked eye vision improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of spontaneous fetal loss through 28 weeks of pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: augmented GLP-1 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: slowing of gastric emptying (GE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of apheresis treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of inflammatory/procoagulant markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion of patients with plasma residual viremia detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma TXB2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 6-K-P levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Level of plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical or urodynamic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in working speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer mistakes made
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for 3D system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transcutaneous CO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acquisition rate of appropriate and sufficient specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody levels against vaccine-preventable infectious diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxygenation ratio (Pao2/Fio2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incident hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreased interleukin (IL) 5 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PSEI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of stay in the intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: length of stay in the hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for circulatory and ventilatory support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correct identification of anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of tachycardia
Endpoint domain: Adverse events/effects
Primary endpoint: Cervical lesions >= CIN 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thalamus volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Putamen volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite outcome of death, stroke, myocardial infarction, repeat revascularization, or new renal-replacement therapy
Endpoint domain: Mortality/survival
Primary endpoint: gap-free regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: narrower gaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to COX-2 inhibitors
Endpoint domain: Adverse events/effects
Primary endpoint: Atracurium use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women who obtained a Pap test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to have a Pap test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-year recurrence-free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: minor chronic complications (persistent arytenoid edema, benign polypoid lesion)
Endpoint domain: Adverse events/effects
Primary endpoint: Higher HOA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halo size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VA under low-contrast conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulty performing bathing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dependence in walking and transferring
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of syllables stuttered (%SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact time used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: High-density lipoprotein cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes